China Pharmaceuticals & Healthcare Report Q3 2018

China Pharmaceuticals & Healthcare Report Q3 2018

BMI View:

Pharmaceutical firms will continue to build their presence in China, aligning themselves with the government's push todevelop the local medicines sector. While ongoing challenges with regards to medicine pricing and the impact of low levels ofintellectual property protection will continue to pose risks to China's pharmaceutical market growth, government commitment toimproving the operating environment will support a greater multinational presence over the long-term.

BMI Industry View
Industry Forecast
Pharmaceutical Market Forecast
Healthcare Market Forecast
Prescription Drug Market Forecast
Patented Drug Market Forecast
Generic Drug Market Forecast
OTC Medicine Market Forecast
Pharmaceutical Trade Forecast
Industry Risk/Reward Index
Asia Pacific Pharmaceuticals: Divergent Regional Trends Will Shape Drugmaker Opportunities
China Risk/Reward Index
Regulatory Development
Regulatory Review
Market Overview
Industry Trends And Developments
Competitive Landscape
Company Profile
Bayer HealthCare
China Shijiazhuang Pharmaceutical Group (CSPC)
Eli Lilly (Lilly China)
Merck & Co
Merck KGaA
North China Pharmaceutical Corporation
Sanofi - Q3 2018
Shanghai Pharmaceuticals Holding Co
13th Five-Year Plan
13th Five-Year Plan: Key Points
Demographic Forecast
Demographic Outlook
Pharmaceuticals & Healthcare Glossary

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook